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Abstract
Background: Histological phenotype and clinical behaviour of malignant tumours are not only dependent on alterations in the
epithelial cell compartment, but are affected by their interaction with inflammatory cells and tumour-associated stroma. Studies
in animal models have shown influence of tumour-associated macrophages (TAM) on histological grade of differentiation in colon
carcinoma. Disruption of transforming growth factor beta (TGF-beta) signalling in tumour cells is related to more aggressive
clinical behaviour. Expression data of components of this pathway in tumour-associated stroma is limited.
Methods: Tissue micro arrays of 310 colon carcinomas from curatively resected patients in UICC stage II and III were
established. In a first step we quantified amount of CD68 positive TAMs and expression of components of TGF-beta signalling
(TGF-beta1, TGF-beta receptors type 1 and 2, Smad 3 and 4) in tumour and associated stroma. Further we analyzed correlation
to histological and clinical parameters (histological grade of differentiation (low-grade (i.e. grade 1 and 2) vs. high-grade (i.e. grade
3 and 4)), lymph node metastasis, distant metastasis, 5 year cancer related survival) using Chi-square or Fisher's exact test, when
appropriate, to compare frequencies, Kaplan-Meier method to calculate 5-year rates of distant metastases and cancer-related
survival and log rank test to compare the rates of distant metastases and survival. To identify independent prognostic factors
Cox regression analysis including lymph node status and grading was performed.
Results: High-grade tumours and those with lymph node metastases showed higher rates of TAMs and lower expression of
TGF-beta1. Loss of nuclear Smad4 expression in tumor was associated with presence of lymph node metastasis, but no influence
on prognosis could be demonstrated. Decrease of both TGF-beta receptors in tumour-associated stroma was associated with
increased lymph node metastasis and shorter survival. Stromal TGF-beta receptor 2 expression was an independent prognostic
factor for cancer related survival.
Conclusion: Histological phenotype and clinical behaviour of colon cancer is not only influenced by mutational incidents in
tumour cells but also affected by interaction of tumour tissue with inflammatory cells like macrophages and associated stroma
and TGF-beta signalling is one important part of this crosstalk. Further studies are needed to elucidate the exact mechanisms.
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Background
Tumours do not exclusively consist of neoplastic epithe-
lial cells, but are also accompanied by a stromal compart-
ment composed of a variety of non-malignant cells, such
as fibroblasts, inflammatory cells, and endothelial cells, as
well as extracellular elements [1,2] Nonetheless in the
past cancer research has been focused primarily on onco-
genic events in tumour cells. It has, however, become
increasingly clear that the tumour environment plays an
important role in malignant disease, and a correlation
between (chronic) inflammation and human predisposi-
tion to carcinogenesis has been demonstrated in several
malignancies [3-5].
The majority of leukocytes that infiltrate the neoplastic
stroma consist of macrophages, which are referred to as
tumour-associated macrophages (TAMs)[1,4,6]. Clinical
observations have shown that the presence of abundant
TAMs can be associated with malignant behaviour in
breast, prostatic, ovarian, and cervical carcinomas [4]. For
other types of cancer, such as gastric, lung, and colorectal
carcinomas, opposing data have been reported[4,7-9].
Thus, the biological significance and possible clinical
implications of TAMs' presence are not yet fully under-
stood.
Maintenance of epithelial tissues needs the stroma. When
the epithelium changes, the stroma inevitably follows.
Crosstalk between tumour and stromal compartment is
based on several signalling pathways. One important
cytokine in this context is transforming growth factor beta
(TGF-β). The TGF-β superfamily of secreted polypeptides
consists of three 25 kDa-proteins (TGF-β1, 2 and 3) and
regulates cell proliferation, differentiation, motility, apop-
tosis and extracellular matrix formation in a variety of dif-
ferent cell types [10-12]. TGF-β serves as a tumour
suppressor pathway in the normal colon by inhibiting cell
proliferation and inducing apoptosis [13-15]. During late
stages of colorectal carcinogenesis, TGF-β serves as a
tumour promoter [16,17] and is often over expressed. A
high expression level of TGF-β in the primary tumour is
associated with advanced stages[18], tumour recurrence
[19], and decreased survival[18].
The TGF-β signal is transduced by a pair of transmem-
brane serine-threonine kinase receptors[11]. TGF-β binds
primarily to TGF-β-R2 receptor homodimers, which then
form heterotetrameric complexes with two TGF-β-R1 mol-
ecules. As a consequence, the TGF-β-R2 kinase phosphor-
ylates TGF-β-R1, thereby activating its serine-threonine
kinase. In response to receptor activation, two cytosolic
proteins, Smad2 and Smad3, become transiently associ-
ated with and phosphorylated by the TGF-β-R1 kinase.
After their activation, Smad2 and Smad3 form hetero-
meric complexes with a third homologue, Smad4. These
complexes are translocated to the nucleus, bind to DNA in
a sequence-specific manner, and regulate gene transcrip-
tion[11]. The resulting repression of c-myc and induction
of cyclin-dependent kinase inhibitors as well as cdc25A
phosphatase lead to G1 phase cell cycle arrest.
Most colorectal cancers escape the tumour suppressor
effects of TGF-β as demonstrated by their resistance to the
antiproliferative and apoptotic effects of TGF-β [16,17].
The molecular mechanisms by which colorectal cancers
escape the tumour suppressor effects of TGF-β are an area
of active investigation. A subset of colorectal cancers has
been shown to have mutations or down-regulation of the
type 1 receptor [20], type 2 receptor [21], Smad2 [22,23]
and Smad4 [24-26].
Most studies so far focussed on alterations of the TGF-β
pathway in the tumour cells. In the present study we
investigated in addition to tumour-associated macro-
phages alterations of this signalling in tumour-associated
desmoplastic stroma and their relation to histological
tumour grade, regional and distant metastasis rates and
survival in a group of colon carcinoma patients that
underwent colon resection.
Methods
Tumour samples
Cases of colon adenocarcinomas were retrieved retrospec-
tively from the files of the Department of Pathology at the
University of Erlangen-Nuremberg, Germany. The speci-
men had been formalin-fixed, paraffin-embedded and
tumour diagnosis made on haematoxylin and eosin (HE)
sections. In the present study 310 tumour samples of
patients were included, which underwent radical resec-
tion with formal regional lymph node dissection between
1991 and 2001 and received complete surgical resection
of their colon carcinoma on clinical and pathohistological
examination. Only solitary colon carcinomas except
appendix tumours were included. Further exclusion crite-
ria were: anamnestic or synchronous other malignant
tumours, known familial adenomatous polyposis, colitis
ulcerosa or Crohn's disease, neoadjuvant therapy, syn-
chronous distant metastases, emergency operation, peri-
operative death and unknown tumour stage at the end of
follow up. Clinical data is summarized in table 1. The
study was carried out in compliance with the Helsinki
Declaration. Ethics Committee, Faculty of Medicine, Uni-
versity of Erlangen-Nuremberg approved research on ano-
nymized archived tumor material of patients in a general
statement from January 24th, 2005.
Tissue micro array technique
A map of the receiver blocks was prepared with coordi-
nates for each sample to correctly identify the tumour
samples. Under a microscope nonnecrotic carcinomaBMC Cancer 2007, 7:156 http://www.biomedcentral.com/1471-2407/7/156
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areas and surrounding areas of immediately adjacent
desmoplastic stroma were marked with an indelible pen
on the HE whole section of each donor block.
The tissue micro arrayer (Beecher Instruments, Wood-
land, USA) was used as follows: cores of 0.6 mm diameter
were punched from the donor blocks and positioned in a
recipient paraffin array block in smaller holes of 0.4 mm
for best adhesion of the samples to the array block. Three
cores of tonsil tissue were positioned on the upper left cor-
ner of each recipient block for correct orientation on the
array of the recipient block. The array blocks were then
incubated for 30 min at 37°C to improve adhesion
between cores and paraffin of the recipient block. After-
wards the blocks were cut with a standard microtome
(Microm, Heidelberg, Germany).
Immunohistochemistry
Sections of 5 μm from the fourteen tissue arrays were cut
onto silane-treated Super Frost slides (CML, Nemours,
France) and left to dry overnight. The slides were depar-
affinized in xylene and rehydrated in pure ethanol.
Endogenous peroxidase was blocked using 3 % hydrogen
peroxide in methanol for 30 min. The slides were then
placed in a microwave oven in citrate buffer (TGF-β1,
TGF-β-R1, TGF-β-R2, Smad3, CD68) for 45 min at 120 to
85°C for antigen retrieval with a subsequent biotin-
streptavidin-peroxidase detection technique or in TRS6
(DAKO, Hamburg, Germany) buffer (Smad4) at the same
processing conditions with subsequent tyramide signal
amplification coupled alkaline phosphatase (DAKO,
Hamburg, Germany) -Fast Red (Sigma-Aldrich, Munich,
Germany) detection technique. All slides were then proc-
Table 1: Clinical data of included colon carcinoma patients
patient data
number of patients n = 310
of these: male n = 189 (61%)
female n = 121 (39%)
median age 64 y (range 28–91 y)
median follow up 91 mo (range 1–177 mo)
adjuvant chemotherapy n = 48 (16%)
tumour site
caecum n = 31 (10.0%)
colon ascendens n = 51 (16.5%)
flexura hepatica n = 21 (6.8%)
colon transversum n = 32 (10.3%)
flexura lienalis n = 15 (4.8%)
colon descendens n = 14 (4.5%)
colon sigmoideum n = 146 (47.1%)
tumour stage (UICC) or lymph node metastasis
II or N0 n = 178 (57.4%)
III or N+ n = 132 (42.6%)
grading
low-grade (G1 and G2) n = 257 (82.9%)
high-grade (G3 and G4) n = 53 (17.1%)
depth of invasion
pT2 n = 24 (7.7%)
pT3 n = 255 (82.3%)
pT4 n = 31 (10.0%)
distant metastasis after 5 years follow up n = 62 (20.0%)BMC Cancer 2007, 7:156 http://www.biomedcentral.com/1471-2407/7/156
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essed manually. Antibodies to TGF-β1 (mouse anti-
human monoclonal, clone TGFB17, dilution 1:20, Novo
Castra, Newcastle upon Tyne, Great Britain), TGF-β-R1
(mouse anti-human monoclonal, clone 8A11, dilution
1:100, Novo Castra, Newcastle upon Tyne, Great Britain),
TGF-β-R2 (goat anti-human polyclonal, AF-241-NA, dilu-
tion 1:100, Wiesbaden, Germany), Smad3 (rabbit anti-
human polyclonal, 51–500, dilution 1:200, Zymed, San
Francisco, USA), Smad4 (mouse anti-human mono-
clonal, sc-7966, dilution 1:50, Santa Cruz Biotechnology,
Heidelberg, Germany), CD68 (mouse anti-human mono-
clonal, clone PG-M1, dilution 1:200, DAKO, Hamburg,
Germany) were used. The slides were counterstained with
Mayer's haemalaun. To exclude non-specific reactions of
secondary antibodies or the different detection systems
control specimen were processed without primary anti-
bodies. In the CD68 staining four categories of macro-
phage infiltration of the tumour tissue were assessed
(none (0), mild (1), intermediate (2), strong (3), see fig.
1). In the TGF-β1 staining four degrees of cytoplasmatic
staining intensity (none (0), mild (1), medium(2), strong
(3), fig. 1) in tumour and surrounding stroma were
assessed separately. For the TGF-β-R1 and TGF-β-R2 mem-
branous staining the same four categories were applied
(fig. 1). Presence or absence of nuclear and cytoplasmatic
staining was assessed for Smad 3 and 4 in tumour and sur-
rounding stroma (for examples [see Additional file 1]).
Statistical analysis
The Kaplan-Meier method was used to calculate 5-year
rates of distant metastases and cancer-related survival. The
log rank test was used to compare the rates of distant
metastases and survival. To identify independent prog-
nostic factors Cox regression analysis including lymph
node status and grading was performed. To compare fre-
quencies Chi-square test, or Fisher's exact test when
appropriate, was used. A p-value of less than 0.05 was
considered to be significant. All analyses were performed
using the statistical software SPSS for Windows Version 13
(SPSS Inc., Chicago, USA).
Results
The results are summarized in table 2.
TAMs
Macrophages in tumour-associated stroma were more
abundant than those infiltrating tumour tissue (mean
score 1.8 vs. 0.5). We found significantly higher levels of
tumour-associated macrophages in high-grade tumours
(p < 0.001) and tumours with lymph node metastases (p
= 0.019). 58% (167 of 287) of tumours with no or only
mild infiltration by TAMs compared to 45% (9 of 20) of
tumours showing intermediate and strong infiltration had
no lymph node metastases. There were no significant dif-
ferences in 5-year survival (87% vs. 80%) or distant
metastases (19.4% vs. 30.0%) between the two groups (p
= 0.261 and p = 0.241 respectively).
Components of TGF-β pathway in tumour tissue
In 296 of 308 tumours (96%) expression of TGF-β1 could
be demonstrated. Low-grade tumours showed higher
TGF-β1 expression (p = 0.009; mean expression level 1.40
for low-grade vs. 0.91 for high-grade tumours). No corre-
lation between TGF-β1 expression and lymph node
metastasis, cancer related survival or distant metastasis
could be demonstrated.
Only few tumours showed expression of TGF-β receptors
(27% or 84 of 309 for type1; 5% or 14 of 295 for type 2).
The rate of receptor expression was not linked to histolog-
ical grade, regional or distant metastasis or survival.
In the majority of tumours (nuclear or cytoplasmatic)
expression of Smad3 (91%; 279 of 309 tumours) and
Smad4 (100% or all 305 tumours) was found. Most
tumours showed nuclear expression of Smad3 (57%; 176
of 309) and Smad4 (86%; 261 of 305), but no correlation
to histological grade could be demonstrated. More nodal
positive tumours (93% or 122 of 131) than cases without
lymph node metastasis (80% or 139 of 174) showed
nuclear Smad4 expression (p = 0.004). No correlation was
found between expression of Smads and distant metasta-
sis or survival.
Components of TGF-β pathway in tumour-associated 
stroma
Expression of TGF-β1 in tumour-associated stroma could
not be demonstrated. Expression of TGF-β receptors and
Smads in stroma was restricted to spindled and some-
times stellar stromal cells apparently representing fibrob-
lasts and myofibroblasts. In most cases TGF-β receptors
were expressed in the tumour-associated stroma (60% or
188 of 310 for type 1; 60% or 186 of 309 for type 2). For
both receptors no correlation to histological grade was
found. Higher TGF-β receptor expression in stroma was
associated with significant decrease of nodal positive
tumours (table 2, p = 0.033 for type 1 and p = 0.001 for
type 2). This was partially reflected by significantly better
5-year cancer related survival for receptor positive com-
pared to negative cases in the nodal positive group (type
1: 86% vs. 69%; p = 0.011 and type 2: 83% vs.76%; p =
0.032). TGF-β receptor expressing cases showed a trend
towards lower rates of distant metastasis, although this
difference was not significant (table 2; 24.5% vs. 12.3%; p
= 0.072 for type 1 and 25.4% vs. 16.6%, p = 0.087 for type
2).
Nuclear expression in the stroma was detected in 46%
(143 of 310) of tumours for Smad3 and 97% (301 of 309)BMC Cancer 2007, 7:156 http://www.biomedcentral.com/1471-2407/7/156
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for Smad4. No correlation to histological grade, local and
distant metastasis or survival could be demonstrated.
Multivariate analysis
In univariate analysis using log rank test presence of
lymph node metastasis (identical to tumour stage: 5-year
cancer-related survival rate: N0 or II: 92.1% vs. N+ or III:
79.5%, p <0,001, table 3), vessel infiltration (V0: 89.0%
vs. V1: 58.3%, p < 0,001) and TGF-β-R2 expression in
tumour-associated stroma (negative: 82.3% vs. positive:
89.3%, p = 0,003) showed statistically significant correla-
tion to cancer-related survival, whereas for all other fac-
tors no association could be demonstrated (see table 3).
On multivariate analysis using Cox regression analysis
besides vessel infiltration and lymph node status expres-
sion of TGF-β-R2 in the stroma (RR 2.2, 95%CI 1.2–3.8, p
Immunohistochemical analysis of tumor and associated stroma Figure 1
Immunohistochemical analysis of tumor and associated stroma. Examples for degree of TAM infiltration in CD68 
staining and levels of expression of TGF-β1 and TGF-β-R2 in tumour and associated stroma. Note change of differentiation 
grade with increase in TAMs.BMC Cancer 2007, 7:156 http://www.biomedcentral.com/1471-2407/7/156
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= 0.007, table 3) was an independent prognostic factor for
cancer-related survival as reflected in Kaplan-Meier sur-
vival curve (see Fig. 2).
Discussion
Macrophage functions are profoundly affected by micro-
environmental signals and can range from powerful
induction of inflammatory responses to immunosuppres-
sion [27]. Although it has been demonstrated previously
that macrophages are capable of killing tumour cells in
vitro and in vivo, evidence is now emerging in support of a
tumour-promoting role for macrophages, and it has
recently been hypothesized that macrophages, residing
within neoplastic tissues, are educated by tumour cells to
perform auxiliary oncogenic functions such as matrix
break-down and induction of angiogenesis [27-30]. In the
present study we found higher levels of TAMs in high-
grade tumours and tumours with lymph node metastasis.
Although there was a trend towards lower rates of distant
metastasis and better survival rates in TAM rich tumours,
this difference was not statistically significant. As this
group accounts for less than 7% of tumours in our study
this result might not be reproducible in larger series.
Nonetheless several observations could explain these
apparently contradictory effects of macrophages in dis-
ease outcome. In a recent experimental study the level of
macrophage accumulation was found to correlate with
macrophage functionality: high-level secretion of mono-
cyte chemoattractant protein-1 (MCP-1) resulted in mas-
sive infiltration of macrophages with subsequent tumour
regression. By contrast, low-level secretion of MCP-1 led
to moderate infiltration of macrophages and melanoma
progression [31]. Second, macrophage activity may alter
over time as a consequence of tumour-induced immune
dysfunction, since nitric oxide production, which is a
major effector molecule for tumour cell killing, was sup-
pressed in macrophages of tumour-bearing mice [32].
Third, a conceptual framework referred to as the so called
macrophage balance hypothesis has been proposed,
defining two different macrophage populations ranging
from polarized potent killer/effector M1 cells to alterna-
tively activated M2 macrophages with tumour-promoting
characteristics. In a recently published study, the presence
Kaplan-Meier survival curve for TGF-β-R2 expression in  tumor-associated stroma Figure 2
Kaplan-Meier survival curve for TGF-β-R2 expression 
in tumor-associated stroma. Cancer-related survival of 
colon carcinoma patients according to TGF-β-R2 expression 
in tumour-associated stroma.
Table 2: Content of tumour-associated macrophages and expression of TGF-β components in tumour and -associated stroma
tumour TAMs TGF-β1T G F - β-R1 TGF-β-R2 Smad3 Smad4
nl o w  
(0–1)
high 
(2–3)
p 
value
low 
(0–1)
high 
(2–3)
p 
value
low 
(0–1)
high 
(2–3)
p 
value
neg. pos. p 
value
neg. pos. p 
value
neg. pos. p 
value
low-grade 248 7 <0.00
1
165 90 0.009 239 16 0.148 245 10 0.278 111 146 0.907 39 214 0.295
high-grade 39 13 44 9 47 7 50 4 22 30 5 47
N0 167 9 0.019 113 63 0.202 163 14 0.581 167 10 0.630 79 99 0.579 35 139 0.004
N+ 120 11 96 36 123 9 128 4 54 77 9 122
5 ycrs 87.0 80.0 0.261 85.6 88.8 0.459 86.4 87.0 0.787 87.0 78.6 0.631 86.1 86.6 0.991 92.5 85.4 0.896
5 ydm 19.4 30.0 0.241 18.7 22.6 0.463 19.9 17.4 0.851 19.9 21.4 0.701 19.5 19.9 0.795 17.3 20.7 0.419
stroma TAMs TGF-β1T G F - β-R1 TGF-β-R2 Smad3 Smad4
nl o w  
(0–1)
high 
(2–3)
p 
value
low 
(0–1)
high 
(2–3)
p 
value
low 
(0–1)
high 
(2–3)
p 
value
neg. pos. p 
value
neg. pos. p 
value
neg. pos. p 
value
low-grade 152 104 0.134 256 0 n.a. 162 94 1.000 98 158 0.229 140 117 0.653 7 249 1.000
high-grade 26 28 52 0 34 20 25 28 27 26 1 52
N0 59 39 0.141 176 0 n.a. 102 76 0.033 56 121 0.001 98 80 0.627 5 172 1.000
N+ 119 93 132 0 94 38 67 65 69 63 3 129
5 ycrs 84.1 87.8 0.897 86.4 n.a. n.a. 84.7 89.5 0.245 82.3 89.3 0.003 87.5 85.4 0.753 83.3 86.5 0.812
5 ydm 12.6 20.0 0.643 20.7 n.a. n.a. 24.5 12.3 0.072 25.4 16.6 0.087 21.0 18.9 0.392 14.3 20.2 0.582
5 ycr: 5 year cancer related survival (%); 5 ydm: 5 year rate of distant metastasis (%); n.a.: not available.BMC Cancer 2007, 7:156 http://www.biomedcentral.com/1471-2407/7/156
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of macrophages directed tumours towards a histologically
more malignant phenotype characterized by extensive
stromal reaction, disorganized matrix deposition, and
neovascularization [33]. Nonetheless, depletion of mac-
rophages deprived tumour inhibitory functions as well,
resulting in enhanced growth and decreased survival,
emphasizing the complexity of the proposed macrophage
balance. We think balance between the following actions
of tumour-associated macrophages could account for
some observations in the present study: At the primary
tumour site macrophage dependent and cytokine medi-
ated promoting activity might increase local infiltrative
growth, enhancement of lymphangiogenesis and lym-
phatic vessel infiltration. On the other hand tumouricidal
activity of macrophages might be restricted to single and
isolated tumour cells on invasion front and founder cells
of early hematogenic metastases. Reducing the number of
macrophages per se, which has been proposed as a thera-
peutic strategy, may therefore not constitute the most
optimal approach. However, specifically counteracting
tumour-promoting characteristics and/or enhancing mac-
rophage tumouricidal activity might be promising for
future therapies. The second question we addressed in this
study was whether alterations in TGF-β signalling are
related to histological tumour grade and clinical behav-
iour of colon cancers. First we analyzed important factors
of TGF-β signalling pathway in the epithelial component
of the tumours. Immunostainable TGF-β1 has been
detected in the malignant epithelial cells in the majority
of our investigated cases of colon carcinomas and expres-
sion was shown to be higher in low-grade tumours, as
shown recently [34], whereas we found no correlation to
lymph node metastases, tumour stage or survival,
although there was a non-significant trend towards lower
TGF-β1 expression in tumours with regional lymph node
metastases. This is in contrast to studies, where TGF-β1
overexpression in advanced stages of colorectal cancers
has been reported and the intensity of the staining seems
Table 3: Results of univariate and multivariate analysis
univariate analysis
score n 5 year survival rate SE p value
pT 2 24 100 0.226
3 255 85.6 2.2
43 1 8 3 . 0 6 . 9
grading low-grade 257 86.9 2.2 0.446
high-grade 53 84.8 5
lymph node status N0 or II 178 92.1 2.1 <0.001
or stage N+ or III 132 79.5 3.5
vessel infiltration V0 285 89.0 1.9 <0.001
V1 24 58.3 10.1
chemotherapy applied 261 87.1 2.1 0.700
not applied 49 83.5 5.3
TGF-β1 in tumour low (0–1) 209 85.5 2.5 0.462
high (2–3) 99 88.6 3.2
Smad3 in tumour negative 133 88.1 2.9 0.941
positive 176 85.3 2.7
Smad4 in tumour negative 44 92.5 4.2 0.896
positive 261 85.4 2.2
TGF-β-R1 in stroma negative 122 83.8 3.4 0.121
positive 188 88.3 2.4
TGF-β R2 in stroma negative 123 82.3 3.5 0.003
positive 186 89.3 2.3
multivariate analysis
score n relative risk RR 95% confidence 
intervall
p value
TGF-β R2 in stroma negative 122 1
positive 186 2.2 1.2–3.8 0.007
lymph node status N0 177 1
N+ 131 2.1 1.2–3.8 0.012
vessel infiltration V0 284 1
V1 24 4.1 2.1–7.9 <0.001BMC Cancer 2007, 7:156 http://www.biomedcentral.com/1471-2407/7/156
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to correlate with advancing stages of tumour progres-
sion[35,36]. However, interpretation of these studies is
complicated by difficulties associated with distinguishing
the biologically inactive, latent form of TGF-β1 from its
activated form.
Most tumours in the present study showed no detectable
TGF-β receptor expression. The loss of TGF-β receptor
expression in colon cancer either through mutation or
downregulation has been reported [20,21], but like in our
study no correlation to histological grade or clinical out-
come was found[37]. In contrast to loss of TGF-β recep-
tors in tumour tissue we found frequent activation of
Smad signalling indicated by nuclear expression of Smad3
and Smad4 in tumour and surrounding stroma, but only
nuclear expression of Smad4 in the malignant epithelial
component was correlated to presence of lymph node
metastasis. Although experimental data suggest tumour
suppressive effects of functionally active Smad4[38,39]
and loss of Smad4 in colorectal cancer is associated with
advanced stage disease, presence of lymph node metasta-
sis and poor prognosis [40-43], others reported retained
Smad4 expression in high-grade colorectal carcinoma and
suggested loss of Smad4 is a late event in colorectal car-
cinogenesis [44]. In our study no influence of reduced
Smad4 expression on prognosis was found. A possible
explanation could be that in our study nodal positive
cases (i.e. stage III patients) had an excellent 5 year sur-
vival of almost 80% indicating good local tumor control.
The reduction of local recurrences possibly through
extended lymphadenectomy could eliminate the prognos-
tic influence of reduced Smad4. Activation of Smad sig-
nalling in our cases as indicated by frequent nuclear
expression in the absence of TGF-β-R expression might
occur primarily through TGF-β independent mechanisms,
e.g. activin signalling [45]. Most authors so far focused
primarily on the malignant epithelial component in
tumours, so expression data of components of TGF-β
pathway in tumour-associated stroma is rare. Unlike oth-
ers [21] we found no expression of TGF-β1 in stroma. In
our study frequent nuclear expression of Smads showed
no correlation to tumour grade or clinical outcome. The
most important finding in our study was an association of
expression of both TGF-β receptors to presence of regional
metastases. In patients with regional metastasized
tumours decreased receptor expression in tumour-associ-
ated stroma was associated with shorter survival, whereas
incidence of distant metastases showed only minor non-
significant increase. Most importantly besides the well-
established influence of lymph node metastasis and vessel
infiltration on cancer-related survival in our study we were
able to show that TGF-β-R2 expression in the stroma is an
independent prognostic factor. Main effector cells for
TGF-β1 in tumour-associated stroma are fibroblasts and
myofibroblasts and decrease of TGF-β receptor expression
in stroma as in epithelial tumour tissue might occur via
mutation or downregulation [20,21] and reflects func-
tional alteration of TGF-β signalling. Paracrine effects of
TGF-β in the stroma can be summarized as locally tumour
promoting and implicate stimulation of angiogenesis,
escape from immunosurveillance and recruitment of
myofibroblasts (as reviewed in [46]). As in models of
tumour escape from chemotherapy[47], disruption of
TGF-β signalling in the stroma via decreased receptor
expression might drive tumour evolution towards a pro-
metastatic phenotype. This might account for decreased
survival, although other mechanisms, e.g. reduction of
indirect antiproliferative TGF-β feedback effects from
stroma to tumour, are conceivable.
Conclusion
In summary not only mutational incidents in tumour
cells but also interaction of tumour tissue with inflamma-
tory cells like macrophages and associated stroma through
TGF-β signalling modulates histological phenotype and
clinical progression in colorectal cancer. Further studies
are needed to clarify the underlying mechanisms.
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